A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse
events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor
effect of TQB3473 tablets in Chinese adult patients with Relapsed or refractory hematological
malignancies.